Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection 2020 - A Pipeline Insight

Dublin, Feb. 21, 2020 (GLOBE NEWSWIRE) -- The "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights into the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Products covered by Phase

• Phase III, Phase II, Phase I
• Pre-clinical & Discovery
• Inactive (Discontinued and Dormant)

Overview of pipeline development activities for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Scope of the report

• Provides an overview of therapeutic pipeline activity for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection

Key Benefits:

• Establish a comprehensive understanding of the current pipeline scenario across Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection to formulate effective R&D strategies
• Assess challenges and opportunities that influence Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection to enhance and expand business potential and scope

Key Topics Covered:

1. Report Introduction

2. Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Disease Overview

3. Pipeline Outlook

• An Overview of Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection

4. Comparative Analysis

5. Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutic Products in Clinical Stage
5.1 Drug Name : Company Name

6. Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutic Products in Non-clinical Stage
6.1 Drug Name : Company Name

7. Therapeutic Pipeline Analysis

• Pipeline Analysis by Route of Administration
• Pipeline Analysis by Stage and Route of Administration
• Pipeline Analysis by Molecule Type
• Pipeline Analysis by Stage and Molecule Type

8. Inactive Pipeline Products
8.1 Drug Description

• Research and Development Studies
• Product Development Activities
• Reason for dormancy/discontinuation

Appendix

Report Methodology

Companies Mentioned

• Atriva Therapeutics GmbH
• Autoimmune Technologies LLC
• CEL-SCI Corp
• Fab'entech SA
• GeneCure LLC
• Nanotherapeutics Inc
• Novavax Inc
• Oncovir Inc
• Phelix Therapeutics LLC

For more information about this report visit https://www.researchandmarkets.com/r/jrgdap

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900